RT Journal Article
T1 Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test.
A1 Rodríguez Villodres, Angel
A1 Gálvez Benítez, Lydia
A1 Arroyo, Manuel J
A1 Méndez, Gema
A1 Mancera, Luis
A1 Vila Domínguez, Andrea
A1 Lepe Jímenez, José Antonio
A1 Smani, Younes
K1 Escherichia coli
K1 Piperacillin
K1 algorithm
K1 beta-lactamase
K1 beta-lactamase inhibitor
K1 machine learning
K1 resistance
K1 tazobactam
AB The excessive use of piperacillin/tazobactam (P/T) has promoted the emergence of P/T-resistant Enterobacterales. We reported that in Escherichia coli, P/T contributes to the development of extended-spectrum resistance to β-lactam/β-lactamase inhibitor (BL/BLI) (ESRI) in isolates that are P/T susceptible but have low-level resistance to BL/BLI. Currently, the detection of P/T resistance relying on conventional methods is time-consuming. To overcome this issue, we developed a cost-effective test based on MALDI-MS technology, called MALDIpiptaz, which aims to detect P/T resistance and ESRI developers in E. coli. We used automated Clover MS Data Analysis software to analyse the protein profile spectra obtained by MALDI-MS from a collection of 248 E. coli isolates (91 P/T-resistant, 81 ESRI developers and 76 P/T-susceptible). This software allowed to preprocess all the spectra to build different peak matrices that were analysed by machine learning algorithms. We demonstrated that MALDIpiptaz can efficiently and rapidly (15 min) discriminate between P/T-resistant, ESRI developer and P/T-susceptible isolates and allowed the correct classification between ESRI developers from their isogenic resistance to P/T. The combination of excellent performance and cost-effectiveness are all desirable attributes, allowing the MALDIpiptaz test to be a useful tool for the rapid determination of P/T resistance in clinically relevant E. coli isolates.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/19696
UL http://hdl.handle.net/10668/19696
LA en
DS RISalud
RD Apr 19, 2025